Apremilast Under Review for Mild to Moderate Plaque Psoriasis
The sNDA is supported by data from the multicenter, double-blind, placebo-controlled phase 3 ADVANCE trial.
Psoriasis
Baseline Patient Characteristics May Predict Psoriasis Course
Among patients with plaque phenotype, high disease activity, and scalp lesions, 52 percent developed severe disease
Sarna Eczema Relief Whipped Foam Now Available
The whipped foam formulation allows for rapid absorption to provide fast relief.
Guselkumab Benefits Observed Through 2 Years in Psoriatic Arthritis Trial
The DISCOVER-2 study aimed to evaluate multiple clinical outcomes including joint and skin symptoms and radiographic progression in patients with psoriatic arthritis.
Amgen Looks to Expand Apremilast Plaque Psoriasis Indication
Results showed that apremilast met the primary end point achieving a statistically significant improvement in sPGA response at week 16 compared with placebo.
Bimekizumab May be Superior to Ustekinumab for Plaque Psoriasis
More patients met targets for improvement in Psoriasis Area and Severity Index, Investigator’s Global Assessment response at week 16
Deucravacitinib Superior to Apremilast in Second Psoriasis Trial
The double-blind, placebo and active-controlled POETYK PSO-2 trial included 1022 patients 18 years of age and older with moderate to severe plaque psoriasis.
Clinical Challenge: Rash on Soles of Feet
A woman presents for evaluation of a rash affecting both feet that prevents her from walking properly because of pain.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
RediTrex Now Available for RA, pJIA, Psoriasis Treatment
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
